Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZACHEL versus LORAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZACHEL versus LORAZ.
CHLORDIAZACHEL vs LORAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.
Binds to gamma-aminobutyric acid (GABA) type A receptors at the benzodiazepine binding site, potentiating the effect of GABA, leading to increased chloride ion influx, neuronal hyperpolarization, and inhibition of neurotransmission.
Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.
2-6 mg orally or intravenously daily in divided doses; usual range 2-10 mg/day
None Documented
None Documented
Clinical Note
moderateClorazepic acid + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol."
Clinical Note
moderateParent: 5-30 hours (mean 15 hours); active metabolite desmethylchlordiazepoxide: 10-20 hours; further metabolite demoxepam: 24-96 hours; clinical context: causes drug accumulation with chronic dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life: 12–15 hours in healthy adults. Extended in elderly (15–20 hours), hepatic impairment (up to 50 hours), and obesity.
Renal: 50-70% as metabolites (mainly oxazepam and desmethylchlordiazepoxide); biliary/fecal: 10-20% as glucuronide conjugates; 1-2% excreted unchanged.
Renal: ~85% as glucuronide conjugates and ~10% as unchanged drug. Biliary/fecal: ~5%.
Category C
Category C
Benzodiazepine
Benzodiazepine
Lorazepam + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Lorazepam."